GlobalData Healthcare 
Pharmaceutical Technology
FEBRUARY 28, 2023
According to GlobalData, Phase I drugs for Melanoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Pharmaceutical Technology
FEBRUARY 28, 2023
According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 28, 2023
According to GlobalData, Phase III drugs for Paroxysmal Nocturnal Hemoglobinuria have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. The company offers generic medicines and biosimilars through Sandoz. Buy the report here.
Pharmaceutical Technology
FEBRUARY 28, 2023
According to GlobalData, Phase III drugs for Glomerulonephritis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Iptacopan hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Pharmaceutical Technology
FEBRUARY 18, 2023
According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Gevokizumab’s valuation in its risk-adjusted NPV model (rNPV). It is a new molecular entity (NME).
Pharmaceutical Technology
MAY 25, 2023
Adherence to medications – defined as the extent to which patients take medications as prescribed by their healthcare providers – can be a significant clinical challenge. The American Medical Association (AMA) lists additional factors [5] such as fear of potential side effects, the cost of prescriptions and a lack of symptoms as significant.
Pharmaceutical Technology
AUGUST 8, 2022
There’s no dearth of interest, however, in applying digital solutions to healthcare. Jose Castillo-Mancilla, associate professor, School of Medicine, University of Colorado, Anschutz. The digital pill, now marketed by Otsuka Pharmaceuticals, is forecasted to make $27 million in sales in 2022, as per GlobalData.
Expert insights. Personalized for you.
68 
Let's personalize your content